Moreover, the addition of nivolumab, trastuzumab, and trastuzumab–deruxtecan is recommended based on the human epidermal growth factor receptor 2 (HER2) and programmed death ligand 1 status of the tumor [7,8,9,10,11]. Here, ERBB2 is linked to neoplasm.